Description
Created On: 2020-07-15
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Disease
- Antibody
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 262483
Licensed Patents means the patents and patent applications further described and listed:
US13/320,629
United States
Utility
Patent – pending
Licensed Technology means: (i) the Licensed Patents, (ii) the Institutions Research Program IP, and (iii) all of the right, title and interest of each of the Institutions in the Joint Research Program IP, all as further described and listed in this agreement (as amended).
Product means any product the manufacture, sale or use of which either (a) exploits Licensed Technology, or (b) would, but for the License, infringe a Valid Claim.
Intellectual Property or “IP†mean inventions (whether patentable or unpatentable), discoveries, written material, compounds, information, know-how, trade secrets, copyright, designs, plant breeders’ rights, integrated circuit topographies, ideas (including but not limited to any computer software), formulae, algorithms, concepts, proprietary data, techniques, instructions, processes, expert opinions, information, materials, program listings, flow charts, logic diagrams, manuals, specifications, instructions, or any copies of the foregoing in any medium, or the expression thereof.
Intellectual Property Rights or “IP Rights†means any rights in Intellectual Property which a Party owns or is seeking to own, including any regular or provisional patent applications filed in the U.S., Canada or any other jurisdiction, and any divisions, continuations, patents issuing thereon or renewals, or reissues, or extensions and any and all patents and patent applications in other countries corresponding thereto, for the Licensed Technology.
Research Program(s) means the sponsored research relating to the research and development of methods and compounds for the modulation of the SIRPa-CD47 interaction for therapeutic cancer applications undertaken by one or both of the Institutions under the SRA #2, SRA #3, SRA #4 and SRA #5A, SRA #5B, and the Collaboration Agreement.
IPSCIO Record ID: 252854
Licensed Technology shall mean and include but not limited to:
(i) the technologies, inventions and know-how associated with the VCU Invention Disclosures listed,
(ii) SRA (Sponsored Research Agreement) technology, inventor improvement(s), collaboration improvements and any non-inventor improvements(s) that Licensee elects to add to this agreement.
Licensed Patent Rights shall mean (a) those patent applications listed and patents issuing therefrom, any foreign equivalents thereof, and any and all United States (and foreign equivalents of) extensions, substitutions, continuations, confirmations, divisions, reissues, reexaminations, restorations, registrations and continuation-in-part applications that are entitled to the priority date of any such applications, with respect to any or all of the foregoing, in each case as of the effective date and thereafter that are filed or issued during the term of this Agreement, and enforcement rights; (b) those United States and foreign patent applications and patents disclosing, covering or claiming any Licensed Technology and, in each case, any and all United States (and foreign equivalents of) extensions, substitutions, continuations, confirmations, divisions, reissues, reexaminations, restorations, registrations and continuation-in-part applications that are entitled to the priority date of any such applications, with respect to any or all of the foregoing, that are filed or issued during the term of this Agreement, and enforcement rights.
Provisional Serial No. 60/621,537, filed October 25, 2004 – Nuclear Oxysterol, Potent Regulator Of Cholesterol Homeostasis, For Therapy Of Hypercholesterolemia, Hyperlipidemia, and Atherosclerosis
Non-Provisional Serial No. 11/739,330, filed April 26, 2007 – Nuclear Sulfated Oxysterol, Potent Regulator Of Cholesterol Homeostasis, For Therapy Of Hypercholesterolemia, Hyperlipidemia, and Atherosclerosis
Provisional Serial No. 61/154,063, filed February 20, 2009 – 5-Cholesten-3b , 25-diol 3-sulfate (25HC3S), an authentic PPARy agonist and LXR antagonist, or the therapy of inflammatory diseases
SRA Technology means Project Technology (defined in the SRA) and any technology, data, ideas, inventions, discoveries and improvements, and the intellectual property rights therein and thereto including Project Patent Rights (defined in the SRA) and enforcement rights, that are developed, generated, made, conceived or reduced to practice, in whole or in part, by inventor(s), alone or with others, directly or indirectly in the performance or as a result of the SRA Project (defined in the SRA).
IPSCIO Record ID: 282944
Product shall mean any product, service, test, or information, including Clofarabine, which, but for the license granted herein, would infringe one or more claims of a Licensor Patent or is discovered, developed, manufactured, approved, marketed or sold using Licensor Know-How or used with Licensor Know-How.
Licensor has rights in patents and technical information relating to the development and uses of 2-flouro-2-halo substituted purine nucleosides Clofarabine.
Patent shall mean (i) patent applications filed in any country within the Asian Territories; (ii) all divisional, continuation (in whole or in part), reissues, substitute applications and extensions with respect to any of the applications described in (i); (iii) all issued or granted patents resulting from any of the applications described above; and (iv) all issued or granted reissue, re-examination, renewal or extension patents, supplementary protection certificates, and confirmation or registration patents based on any of the patents described in (iii).
Intellectual Property shall mean all inventions, discoveries, know-how, methods, processes, data, information, technology, research tools, compositions, tangible materials and formulas that are invented, discovered, developed or otherwise generated by or for either party or their respective Affiliates prior to or during the term of this Agreement, and all Intellectual Property Rights therein and thereto anywhere in the world.
Intellectual Property Rights shall mean any and all now known or hereafter existing: (i) rights associated with works of authorship, including exclusive exploitation rights, copyrights, and moral rights; (ii) trademark and trade name rights and similar rights; (iii) trade secret rights; (iv) patents and industrial property rights; (v) other proprietary rights in Intellectual Property of every kind and nature, whether arising by operation of law, by contract or license, or otherwise; and (vi) all registrations, applications, renewals, extensions, combinations, divisions, or reissues of the foregoing, in each case in any jurisdiction throughout the Asian Territories.
IPSCIO Record ID: 279345
Licensed Product shall mean a product comprising a Humanized Antibody, the manufacture, use, offer for sale, sale, or importation of which by an unlicensed third party would infringe one or more Valid Claims of the Licensed Patent Rights, or which incorporates Licensor IP or Licensor Inventions. The term “Licensed Product†does not include chimeric antibodies or murine antibodies.
Humanized Antibody shall mean an antibody that binds to Sphingosine-1-phosphate and is made by Licensor under this Agreement, the antibody comprising murine complementarity determining regions derived from Sphingomabâ„¢ together with human framework regions, and any modifications thereof.
Licensed Patent Rights shall mean the patents and patent applications licensed to Licensor and with respect to which Licensor has the right to authorize and grant sublicenses, as detailed in hereto, including any divisions, renewals, continuations, extensions, reexaminations, reissues, or continuations-in-part (to the extent that any such continuation-in-part claims subject matter as disclosed in the patents and applications listed thereof, as well as any patent that issues from any of the foregoing.
Licensor IP shall mean (i) any Licensor Invention and (ii) all patented and non-patented proprietary technology and information, in any form whatsoever, that is: (a) necessary or useful for making and using the Licensed Products, without regard to whether or not the technology or information is patentable; (b) owned, controlled, or developed by Licensor, as of the Effective Date or hereafter during the term of this Agreement; and (c) provided by Licensor to Licensee hereunder, including, but not limited to discoveries, formulae, materials, practices, methods, knowledge, know-how, processes, trade secrets, ideas, concepts, manufacturing, engineering, standard operating procedures, flow diagrams and charts, quality assurance, quality control data, technical data, manufacturing technology, research data and records, and all other confidential or proprietary technical and business information relating to the humanization of murine antibodies, generation of chimeric antibodies, or any gene expression vectors used in such methods and all improvements or modifications thereto. For purposes of clarity, Licensor IP includes Licensor Inventions that satisfy (a), (b) and (c), above, while Licensor IP does not include Licensed Patent Rights as defined hereunder.
Licensor Invention shall mean any discovery or invention to the extent (i) made or conceived or reduced to practice by or on behalf of Licensor in the performance of the humanization of Licensees Sphingomabâ„¢ antibody under this Agreement, whether or not patentable, and (ii) covering only generally applicable methods or techniques for humanizing antibody proteins or for constructing a vector or reagent used to humanize or express an antibody.
Sphingomabâ„¢ is the original mouse version of this monoclonal antibody.
IPSCIO Record ID: 4576
Modulation of SIRPalpha – CD47interaction for increasing human hematopoietic stem cell engraftment andcompounds thereof.
Compositions and methods fortreating hematologic cancers targeting the SIRPalpha – CD47interaction.
Compositions and methods fortreating leukemia targeting the SIRPalpha – CD47 interaction.
